June 4, 2015.
The active and diverse treatment pipeline for asthma "boasts a striking level of innovation, with many first-in-class products representing significant investment opportunities", according to GBI Research.
GBI's report, Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation, states that while asthma therapy development is dominated by small molecule compounds, with 156 products representing 67% of the pipeline, the research and development landscape has moved towards biologics on an unprecedented scale. There are now 60 biologics in the pipeline, representing a 26% share.
Yasser Mushtaq, Senior Analyst for GBI Research, commented: “There is a high degree of innovation across the entire asthma therapeutics pipeline... Between 2006 and 2015, 65 deals associated with asthma treatment have been completed. Of these, 42 involved a product or products with a disclosed molecular target, 14 of which were first-in-class.” However, 88% of first-in-class pipeline drugs for asthma have not yet been involved in a licensing or co-development deal, emphasizing the strong degree of opportunity available to investors.
Mushtaq added: “Investment in biologics, which would have been considered very risky just over a decade ago, has made a remarkable clinical and commercial impact across various indications, with biologics representing seven of the top 10 best-selling products in 2013."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.